Switching Shiga Toxin (Stx) Type from Stx2d to Stx2a but Not Stx2c Alters Virulence of Stx-Producing Escherichia coli (STEC) Strain B2F1 in Streptomycin (Str)-Treated Mice

Shiga toxin (Stx)-producing Escherichia coli (STEC) strain B2F1 produces Stx type 2d, a toxin that becomes more toxic towards Vero cells in the presence of intestinal mucus. STEC that make Stx2d are more pathogenic to streptomycin (Str)-treated mice than most STEC that produce Stx2a or Stx2c. However, purified Stx2d is only 2- or 7-fold more toxic by the intraperitoneal route than Stx2a or Stx2c, respectively. We hypothesized, therefore, that the toxicity differences among Stx2a, Stx2c, and Stx2d occur at the level of delivery from the intestine. To evaluate that hypothesis, we altered the toxin type produced by stx2d+ mouse virulent O91:H21 clinical isolate B2F1 to Stx2a or Stx2c. Because B2F1 encodes two copies of stx2d, we did these studies in a derivative of B2F1 in which stx2d1 was deleted. Although the strains were equivalently virulent to the Str-treated mice at the 1010 dose, the B2F1 strain that produced Stx2a was attenuated relative to the ones that produced Stx2d or Stx2c when administered at 103 CFU/mouse. We next compared the oral toxicities of purified Stx2a, Stx2c, and Stx2d. We found that purified Stx2d is more toxic than Stx2a or Stx2c upon oral administration at 4 µg/mouse. Taken together, these studies suggest that Stx2 toxins are most potent when delivered directly from the bacterium. Furthermore, because Stx2d and Stx2c have the identical amino acid composition in the toxin B subunit, our results indicate that the virulence difference between Stx2a and Stx2d and Stx2c resides in the B or binding subunit of the toxins.

[1]  R. Lindsey,et al.  The Virulence of Escherichia coli O157:H7 Isolates in Mice Depends on Shiga Toxin Type 2a (Stx2a)-Induction and High Levels of Stx2a in Stool , 2020, Frontiers in Cellular and Infection Microbiology.

[2]  Patrick Cherubin,et al.  Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell , 2019, Infection and Immunity.

[3]  Mark A. Smith,et al.  Shiga Toxin Type 1a (Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro , 2019, Infection and Immunity.

[4]  S. Herrera-León,et al.  Mucus-Activatable Shiga Toxin Genotype stx2d in Escherichia coli O157:H7 , 2017, Emerging infectious diseases.

[5]  E. Maynard,et al.  Reduced Toxicity of Shiga Toxin (Stx) Type 2c in Mice Compared to Stx2d Is Associated with Instability of Stx2c Holotoxin , 2015, Toxins.

[6]  S. Delannoy,et al.  Characteristics of Emerging Human-Pathogenic Escherichia coli O26:H11 Strains Isolated in France between 2010 and 2013 and Carrying the stx 2d Gene Only , 2014, Journal of Clinical Microbiology.

[7]  M. Stevens,et al.  The Locus of Enterocyte Effacement and Associated Virulence Factors of Enterohemorrhagic Escherichia coli , 2014, Microbiology spectrum.

[8]  F. Scheutz Taxonomy Meets Public Health: The Case of Shiga Toxin-Producing Escherichia coli. , 2014, Microbiology spectrum.

[9]  M. Smith,et al.  Oral Intoxication of Mice with Shiga Toxin Type 2a (Stx2a) and Protection by Anti-Stx2a Monoclonal Antibody 11E10 , 2013, Infection and Immunity.

[10]  D. Mazel,et al.  Silent Mischief: Bacteriophage Mu Insertions Contaminate Products of Escherichia coli Random Mutagenesis Performed Using Suicidal Transposon Delivery Plasmids Mobilized by Broad-Host-Range RP4 Conjugative Machinery , 2010, Journal of bacteriology.

[11]  A. Mellmann,et al.  Analysis of Collection of Hemolytic Uremic Syndrome–associated Enterohemorrhagic Escherichia coli , 2008, Emerging infectious diseases.

[12]  L. Teel,et al.  One of Two Copies of the Gene for the Activatable Shiga Toxin Type 2d in Escherichia coli O91:H21 Strain B2F1 Is Associated with an Inducible Bacteriophage , 2002, Infection and Immunity.

[13]  A. O’Brien,et al.  Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer , 2002, Molecular microbiology.

[14]  A. O’Brien,et al.  Virulence of Shiga toxin-producing Escherichia coli (STEC) in orally-infected mice correlates with the type of toxin produced by the infecting strain. , 1998, Japanese journal of medical science & biology.

[15]  A. O’Brien,et al.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.

[16]  J. Samuel,et al.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality , 1994, Infection and immunity.

[17]  A. Melton,et al.  Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model , 1993, Infection and immunity.

[18]  J. Kaper,et al.  Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector , 1991, Infection and immunity.

[19]  Y. Takeda,et al.  Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. , 1990, Microbial pathogenesis.

[20]  A. O’Brien,et al.  Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay , 1988, Journal of clinical microbiology.